Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction.

Case Rep Psychiatry

Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive, MC 0603, La Jolla, CA 92093-0603, USA; California Department of State Hospitals (DSH), Director of Psychopharmacology Services, Bateson Building, 1600 9th Street, Room 400, Sacramento, CA 95814, USA.

Published: October 2016

Clozapine provides a 50%-60% response rate in refractory schizophrenia but has a narrow therapeutic index and is susceptible to pharmacokinetic interactions, particularly with strong inhibitors or inducers of cytochrome P450 (CYP) 1A2. We report the case of a 28-year-old nonsmoking female with intellectual disability who was maintained for 3 years on clozapine 100 mg orally twice daily. The patient was treated for presumptive urinary tract infection with ciprofloxacin 500 mg orally twice daily and two days later collapsed and died despite resuscitation efforts. The postmortem femoral clozapine plasma level was dramatically elevated at 2900 ng/mL, and the cause of death was listed as acute clozapine toxicity. Given the potentially fatal pharmacokinetic interaction between clozapine and ciprofloxacin, clinicians are advised to monitor baseline clozapine levels prior to adding strong CYP450 1A2 inhibitors, reduce the clozapine dose by at least two-thirds if adding a 1A2 inhibitor such as ciprofloxacin, check subsequent steady state clozapine levels, and adjust the clozapine dose to maintain levels close to those obtained at baseline.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107233PMC
http://dx.doi.org/10.1155/2016/5606098DOI Listing

Publication Analysis

Top Keywords

clozapine
9
interaction clozapine
8
orally daily
8
clozapine levels
8
clozapine dose
8
ciprofloxacin
4
ciprofloxacin clozapine
4
clozapine fatal
4
fatal underappreciated
4
underappreciated interaction
4

Similar Publications

Inhibition of the Basolateral Amygdala to Prelimbic Cortex Pathway Enhances Risk-taking during Risky Decision-making Shock Task in Rats.

Physiol Behav

January 2025

Beijing Key Laboratory of Learning and Cognition, College of Psychology, Capital Normal University, Beijing, PR China. Electronic address:

Many animal studies have explored decision-making under risk and punishment, particularly regarding potential rewards, but less focus has been placed on contexts involving net losses. Understanding decision-making under net loss conditions can shed light on the neural mechanisms involved. The basolateral amygdala to prelimbic cortex (BLA→PL) pathway is crucial for risky decision-making.

View Article and Find Full Text PDF

Dual inhibition of cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) is a recognized strategy for enhanced anti-inflammatory effects in small molecules, offering potential therapeutic benefits for individuals at risk of dementia, particularly those with neurodegenerative diseases, common cancers, and diabetes type. Alzheimer's disease (AD) is the most common cause of dementia, and the inhibition of acetylcholinesterase (AChE) is a key approach in treating AD. Meanwhile, Caspase-3 catalyzes early events in apoptosis, contributing to neurodegeneration and subsequently AD.

View Article and Find Full Text PDF

: Myoclonus is already associated with a wide variety of drugs and systemic conditions. As new components are discovered, more drugs are suspected of causing this disabling abnormal involuntary movement. This systematic review aims to assess the medications associated with drug-induced myoclonus (DIM).

View Article and Find Full Text PDF

The blood-brain barrier and the distinct brain immunology provide challenges in translating commonly used chemotherapeutics to treat intracranial tumors. Previous reports suggest anti-tumoral effects of antipsychotics, encouraging investigations into potential treatment effects of neuroleptics on brain metastases. For the first time, the therapeutic potential of the antipsychotic drug clozapine in treating melanoma brain metastases (MBM) was investigated using three human MBM cell lines.

View Article and Find Full Text PDF

Background: Schizophrenia is a complex psychiatric disorder, and in patients treated with clozapine, it may induce or exacerbate obsessive-compulsive symptoms (OCS), which negatively affect patients' quality of life, functionality and treatment adherence. Despite its clinical relevance, the reported prevalence and characteristics of clozapine associated OCS vary widely, limiting effective management.

Objective: This scoping review synthesizes evidence on the prevalence of OCS in patients with schizophrenia treated with clozapine and explores treatment characteristics (types, severity, dose, and time to onset/exacerbation).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!